Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

SEMA G 2mg
SEMA G 2mg

SEMA G 2mg

SEMA G 2 mg — research reagent containing semaglutide, a synthetic mono-agonist of the GLP-1 receptor, for laboratory tests. The best documented incretin analogue: half-life up to ~7 days. Vial with lyophilisate, 2 mg of peptide for reconstitution, freedom to select the working concentration. RUO reagent

56,99 €
With code BLACK: 45,59 € Lowest price in the 30 days before the discount: 56,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

SEMA G 2 mg (semaglutide) - GLP-1 receptor mono-agonist - research reagent

  • SEMA G 2 mg — research reagent containing semaglutide, a synthetic mono-agonist of the GLP-1 receptor, for laboratory tests.
  • The best documented incretin analogue: half-life up to ~7 days.
  • Vial with lyophilisate, 2 mg of peptide for reconstitution, freedom to select the working concentration.

Semaglutide is the active substance of registered medicinal products: Ozempic® and Wegovy® (subcutaneous injection) and Rybelsus® (oral form). Semaglutide is available as a pharmaceutical drug only on prescription and requires medical supervision. Reagent SEMA G 2 mg featured on this page is not a substitute for a medicinal product, does not replace medical consultation and is not authorized for administration to humans. These are two different worlds: a registered drug with full pharmaceutical documentation (GMP, clinical trials, characteristics of the medicinal product) and a chemical reagent for laboratory work. Confusing them is a health and legal mistake.

Introduction

The incretin axis – a system of intestinal hormones released in response to food, regulating glycemia, insulin secretion and satiety signals – is one of the most intensively studied endocrine pathways of the last decade. The central element of this axis is GLP-1 (glucagon-like peptide 1), a hormone secreted by the L cells of the intestine – concentrated mainly in its distal section – which combines the regulation of glucose metabolism with the central control of appetite.

Natural GLP-1 has one major drawback from a pharmacological point of view: it is degraded within minutes by the DPP-4 enzyme, which makes it unsuitable as a stable research tool or long-acting drug. SEMA G 2 mg from the line Endogenous is a research reagent containing semaglutide — a synthetic analogue of human GLP-1 designed to bypass this barrier.

The Endogenic line in the Pro-Body catalog groups peptides that represent endogenous molecules or their analogues – signalers that the body produces on its own and which researchers synthetically recreate and modify as molecular tools. Semaglutide is just such an analogue: a core GLP-1 sequence with three modifications that extend its half-life from minutes to approximately seven days and make it the best documented incretin analogue in the literature.

SEMA G 2 mg is supplied in the format vials with lyophilisate for reconstitution – 2 mg semaglutide per vial. The lyophilized form – a freeze-dried powder – is the classic format of the peptide reagent with the highest stability in stock: the peptide without water remains stable for many months, and the researcher independently determines the working concentration at the reconstitution stage.

This distinguishes the vial variant from the ready-made applicator SEMA G PEN 2mg, where a solution with the same peptide content is already prepared at the factory.

Sema G, GLP-1 and the incretin system

Semaglutide – the active compound of SEMA G 2 mg reagent – belongs to the class GLP-1 receptor agonists, i.e. compounds that imitate the action of the natural incretin hormone on its receptor. To understand what this reagent is, you must first distinguish between two concepts: incretins and receptor agonism. Incretins are intestinal hormones released in response to food intake, which enhance glucose-dependent insulin secretion – that is, they enhance the insulin response after a meal more strongly than would result from the increase in blood glucose concentration alone.

The two main incretins are GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide). The incretin effect—the phenomenon in which glucose administered orally produces a greater insulin response than the same amount administered intravenously—was one of the starting points for the entire GLP-1 analogue research program. GLP-1 receptor agonist is a molecule that binds to the GLP-1 receptor (GLP-1R) and activates it, reproducing the natural hormone signal.

Semaglutide is mono-agonist: acts selectively on one receptor – GLP-1R. This is a central feature that distinguishes it from compounds with a broader profile, such as dual-agonists GLP-1+GIP 10mg (two receptors at once) or triple-agonist TRIPLE G PEN 5mg (three receptors). GLP-1R selectivity makes semaglutide the purest tool for studying the GLP-1 axis alone – without overlapping GIP or glucagon signals.

In the Pro-Body catalog SEMA G 2 mg belongs to Pillar II – body composition peptides and metabolic axis; in the store navigation the reagent is among peptides for burning fat tissue. The format of the lyophilized vial is both technical and strategic: the lyophilized is the most stable form of peptide storage, and the researcher reconstitutes the contents of the vial (2 mg) to a volume selected for the planned molar concentration of the working solution.

What is SEMA G 2 mg - semaglutide, a GLP-1 analogue with three modifications

SEMA G 2 mg is a research reagent containing semaglutide (semaglutide) — a synthetic analogue of human GLP-1 based on the sequence of the natural hormone, in which three structural modifications were introduced. Each of them solves one pharmacokinetic problem of native GLP-1.

Aib8 modification (α-aminoisobutyric acid at position 8). Natural GLP-1 is rapidly cleaved by the enzyme DPP-4 (dipeptidyl peptidase 4) at the eighth position. Replacing the natural amino acid at this site with α-aminoisobutyric acid (Aib) stiffens the molecule at the point of enzymatic attack and makes it resistant to degradation by DPP-4 – the first requirement for long-lasting action.

Acylation with a C18-diacid chain (fatty acid with a linker). A long-chain fatty acid (C18 diacid) is attached to the molecule via a linker. This lipid hook binds semaglutide non-covalently to plasma albumin, the most abundant protein in blood. The albumin-bound peptide is protected from renal filtration and degradation, which further prolongs its presence in the bloodstream.

Chain extending half-life to ~7 days. The combination of resistance to DPP-4 (Aib8) and binding to albumin (acylation) gives semaglutide a half-life of seven days. It is this feature that underpins the once-weekly dosing regimen used in clinical trials of the approved drug formulation – a single exposure maintains an active concentration for an entire week.

Physicochemical characteristics of SEMA G 2 mg

Parameter Value
Trade name SEMA G 2 mg
Active compound Semaglutide (semaglutide)
Contents of the vial 2 mg semaglutide (lyophilisate for reconstitution)
Line Endogenous
Class GLP-1 receptor mono-agonist (incretin analogue)
Target receptor GLP-1R (GLP-1 receptor, G-protein coupled GPCR)
Modifications Aib8 (DPP-4 resistance), C18-diacid acylation (binding to albumin), chain extension
Sequence Human GLP-1 analogue with substitutions – identity determined by sequence and mass in the batch COA
CAS Number 910463-68-2
Molecular weight ~4113 g/mol
Half-life ~7 days (basis for once-a-week regimen in clinical trials)
Physical form Lyophilisate (freeze-dried powder) in a vial
Alternative variant SEMA G 2 mg PEN – the same peptide content in the factory solution
HPLC purity ≥98%
Identity confirmation Q-TOF mass spectrometry
Registered drugs with semaglutide Ozempic®, Wegovy® (injection), Rybelsus® (oral)

Molecular mechanism of semaglutide - GLP-1 receptor agonism

Semaglutide works by selectively activating the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR) present in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. The mechanism described in the literature covers five related areas.

Glucose-dependent insulin secretion. When bound to GLP-1R on pancreatic beta cells, semaglutide increases insulin secretion – but only in the presence of elevated glucose concentrations. Yeah glucose dependence this is an important feature of the mechanism: the receptor enhances the insulin response when glucose increases and silences it when glucose decreases. This has been described in models as the basis of the profile in which GLP-1R activation regulates glycemia.

Inhibiting glucagon secretion and slowing down gastric emptying. Activation of GLP-1R suppresses the glucose-dependent secretion of glucagon, a hormone that opposes insulin and increases glycemia. At the same time, semaglutide slows down gastric emptying, which in the literature has been associated with a slower influx of glucose from the gastrointestinal tract into the bloodstream and with a prolonged signal of postprandial satiety.

Central action on hypothalamic satiety centers. GLP-1R is found in the hypothalamus – in the centers that regulate appetite and satiety. Studies with semaglutide have reported effects on these centers as part of appetite regulation in a research context. This central arm of the mechanism distinguishes GLP-1 analogues from compounds acting only at the level of the pancreas.

Long half-life as a foundation of pharmacokinetics. Acylation (binding to albumin) and resistance to DPP-4 (Aib8) result in a half-life of seven days. This is a pharmacokinetic feature, not a component of the receptor signaling itself: it allows GLP-1R activation to be maintained consistently throughout the week after a single exposure – the basis of the once-weekly regimen in clinical drug development studies.

Research on metabolism, glycemia and body weight. The SUSTAIN program (glycemic and cardiovascular endpoints) and the STEP program (body weight endpoints) are extensive literature contexts describing the action of the active substance in the form of a drug – a broader class comparison is developed in the article Tirzepatide and Semaglutide. We cite them as the context of the literature, not as a recommendation or suggestion for use — the RUO reagent remains a laboratory tool.

IMPORTANT DISTINCTION – SEMA G 2 mg (lyophilized vial) vs SEMA G 2 mg PEN

The same substance and the same peptide content – 2 mg – in two different forms. This product is vial with lyophilisate: freeze-dried powder, requiring reconstitution, in which the researcher selects the volume of the solvent, and therefore the working concentration; The lyophilisate remains stable in storage longer than the ready solution. The SEMA G 2 mg PEN variant is factory prepared solution: ready for collection without a reconstitution step, with repeatability of subsequent collections, at the expense of freedom in choosing the concentration.

Same compound, same 2 mg content, different form – the difference is only in the form of the reagent, not the molecule. The applicator line also includes variants with higher peptide content: SEMA G PEN 4mg and SEMA G PEN 8mg.

Second axis – SEMA G 2 mg (lyophilized vial) vs SEMA G 2 mg PEN. Both SKUs contain the same compound in the same amount (2 mg) – they only differ in form. The vial allows the freedom to choose the molar concentration and the highest stability in stock (lyophilisate), the applicator – ready for use without a reconstitution step and repeatability of withdrawals from the factory solution. The choice is a decision about the format of the lab work, not about any other relationship.

Third axis – RUO reagent vs registered drug (Ozempic/Wegovy/Rybelsus). This is the most important distinction. Semaglutide is the active substance of registered drugs: Ozempic® and Wegovy® (injection) and Rybelsus® (oral form). These drugs have undergone full clinical trials, have a summary of medicinal product characteristics, are produced under the GMP regime and are available only on prescription under medical supervision. SEMA G 2 mg reagent is not a substitute for any of these medicines — it does not have documentation, pharmaceutical quality or authorization for human administration. It does not replace a medical consultation.

Applications in scientific research

SEMA G 2 mg as an RUO reagent is used in research on the incretin axis and the GLP-1 receptor. The lyophilized vial format is particularly useful when the researcher needs to independently define the starting concentration of the mother solution – reconstitution of 2 mg of peptide to a selected volume allows the molarity to be adjusted to a specific test.

GLP-1 receptor (GLP-1R) signaling. Cell models expressing GLP-1R and animal models of the incretin axis. Endpoints: GPCR activation, cAMP cascade, glucose-dependent insulin secretion in beta cell cultures. Semaglutide’s single-receptor selectivity makes it a reference tool for GLP-1 mono-agonism.

Pharmacokinetics of a long half-life analogue. Studies on the mechanism of prolonged action: the role of acylation (binding to albumin), resistance to DPP-4 (Aib8), time profile of exposure. Semaglutide is a model compound for studying how structural modifications translate into a half-life of days.

Comparative profiles of incretin agonists. Comparison of a mono-agonist (semaglutide) with dual- (GLP-1 + GIP) and triple-agonists (retatrutide) in one arm of the experiment – analysis of how the addition of additional receptors changes the profile of metabolic endpoints. The lyophilisate allows you to prepare a mother solution with a concentration selected for serial dilutions.

Models of metabolism, glycemia and body weight. Animal models of glycemic regulation and energy balance – endpoints consistent with the direction of the SUSTAIN and STEP programs described in the literature on the active substance. All measurements in experimental conditions, on research models.

Summary

SEMA G 2 mg from the Endogenic line is a research reagent containing semaglutide — synthetic mono-agonist of the GLP-1 receptor, the best documented incretin analogue in the literature, supplied in RUO format as a vial with lyophilisate (2 mg of peptide) for reconstitution. Three structural modifications (Aib8 for DPP-4 resistance, C18-diacid acylation for binding to albumin, and an extension chain) extend the half-life of native GLP-1 from minutes to approximately seven days.

The mechanism described in the studies includes glucose-dependent insulin secretion, glucagon inhibition, slowing down of gastric emptying and a central effect on the hypothalamic satiety centers – with the SUSTAIN and STEP programs as the literature context on the active substance. Working with this reagent requires the separation of three axes: mono-agonist (GLP-1R) from dual-agonists (GLP-1+GIP) and triple-agonists (retatrutide); 2 mg lyophilisate vials from the SEMA G 2 mg PEN variant with the same peptide content in the factory solution; and – most importantly – the RUO reagent from the registered drug.

Semaglutide is the active ingredient in Ozempic®, Wegovy® and Rybelsus® – medicines available only by prescription under medical supervision. SEMA G 2 mg reagent does not replace them.

Bibliography

  1. Knudsen LB, Lau J (2019). The Discovery and Development of Liraglutide and Semaglutide. PubMed
  2. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. PubMed
  3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed
  4. Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. PubMed
  5. Drucker D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. PubMed

Chemical reagent Research Use Only. SEMA G 2 mg – semaglutide in a lyophilized vial (Endogenic line) – in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans. Use on animal models only under controlled experimental conditions in authorized research units. Semaglutide is the active substance of the registered drugs Ozempic®, Wegovy® (injection) and Rybelsus® (oral form) authorized by the EMA and FDA – available only with a prescription and under medical supervision.

SEMA G 2 mg reagent is not a substitute for a medicinal product and does not replace a medical consultation. Semaglutide is not currently on the WADA Prohibited List, but the status is subject to change – Registered Athletes (ADAMS) must check the current list before making any decision. The information in the description is of an educational and scientific nature and refers to the results reported in the literature on the active substance – it does not constitute medical advice or administration instructions.